Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer / 한국유방암학회지
Journal of Breast Cancer
;
: 237-247, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-764266
ABSTRACT
PURPOSE:
Breast cancer (BC) is one of the most common malignancies globally, and millions of women worldwide are diagnosed with BC every year. Up to 70% of BC patients are estrogen receptor (ER)-positive. Numerous studies have shown that tamoxifen has a significant therapeutic effect on both primary and metastatic ER-positive BC patients. Although tamoxifen is currently one of the most successful therapeutic agents for BC, a significant proportion of patients will eventually become resistant to tamoxifen, leading to tumor recurrence and metastasis. Knowledge about the development of tamoxifen resistance in BC patients is still limited.METHODS:
We applied a loss-and-gain method to study the biological functional role of cell division cycle associated 8 (CDCA8) in tamoxifen resistance in BC cells.RESULTS:
We found that CDCA8 was significantly elevated in tamoxifen-resistant BC cells. Knockdown of CDCA8 expression significantly inhibited the proliferation of tamoxifen-resistant BC cells and reduced their resistance to tamoxifen. In contrast, overexpression of CDCA8 promoted the growth of tamoxifen-sensitive BC cells and induced their resistance to tamoxifen.CONCLUSION:
In this study, we reported that CDCA8 is a key regulator of tamoxifen resistance in BC, suggesting that CDCA8 may serve as a potential therapeutic target for BC treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Recidiva
/
Tamoxifeno
/
Mama
/
Neoplasias da Mama
/
Ciclo Celular
/
Divisão Celular
/
Apoptose
/
Estrogênios
/
Métodos
/
Metástase Neoplásica
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Journal of Breast Cancer
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS